The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 23

PMID 38256566

Authors

Kyoung Ree Lim

Kwang Jin Chun

Bum Sung Kim

Seunghwa Lee

Affiliations

Soon will be listed here.

Abstract

Background: There is no clinical evidence about the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus disease 19 (COVID-19).

Methods: The dataset is based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea from January, 2018 to April, 2022. Among 9,822,577 patients who were involved in the claims, diabetic patients were divided into two groups based on whether they had a prescription for an SGLT2 inhibitor. The primary outcome was major adverse cardiac and cerebrovascular events (MACCEs), which were a composite of all-cause mortality, myocardial infarction, stroke, and revascularization over 90 days.

Results: A total of 172,682 patients was analyzed. In the propensity score-matched analysis, the rate of MACCE was lower in the SGLT2 inhibitor group compared to the non-SGLT2 inhibitor group (0.89% vs. 1.31%; hazard ratio, 0.71; 95% confidence interval, 0.53-0.94; =0.020). Each of the MACCEs showed no differences between the two groups. The rate of pneumonia was similar between the two groups (4.45% vs. 4.39%; hazard ratio, 1.06; 95% confidence interval, 0.91-1.16; = 0.620).

Conclusions: In the diabetic patients who were diagnosed with COVID-19, SGLT2 inhibitors were associated with improved clinical outcomes in terms of MACCEs. SGLT2 inhibitors might be considered for prescription to diabetic patients in the current context of long COVID-19.

References

Vitale R, Valtis Y, McDonnell M, Palermo N, Fisher N . Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors. AACE Clin Case Rep. 2021; 7(1):10-13. PMC: 7833657. DOI: 10.1016/j.aace.2020.11.019. View

Tereshchenko L, Bishop A, Fisher-Campbell N, Levene J, Morris C, Patel H . Risk of Cardiovascular Events After COVID-19. Am J Cardiol. 2022; 179:102-109. PMC: 9282909. DOI: 10.1016/j.amjcard.2022.06.023. View

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

Fedorchenko Y, Zimba O . Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis. J Korean Med Sci. 2023; 38(11):e93. PMC: 10027540. DOI: 10.3346/jkms.2023.38.e93. View

Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee A, Neubauer S . Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. Heart. 2022; 109(2):119-126. PMC: 9811071. DOI: 10.1136/heartjnl-2022-321492. View

Maayah Z, Ferdaoussi M, Takahara S, Soni S, Dyck J . Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology. 2020; 29(1):269-279. DOI: 10.1007/s10787-020-00732-4. View

Bossi A, Forloni F, Colombelli P . Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends. Diabetes Ther. 2020; 11(7):1605-1606. PMC: 7244936. DOI: 10.1007/s13300-020-00844-8. View

Xie Y, Xu E, Bowe B, Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022; 28(3):583-590. PMC: 8938267. DOI: 10.1038/s41591-022-01689-3. View

Wu M, Chandramouli C, Wong P, Chan Y, Li H, Yu S . Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes Metab. 2022; 48(6):101367. DOI: 10.1016/j.diabet.2022.101367. View

10.

Jiang G, Kiefer R, Sharma D, Prudhommeaux E, Solbrig H . A Consensus-Based Approach for Harmonizing the OHDSI Common Data Model with HL7 FHIR. Stud Health Technol Inform. 2018; 245:887-891. PMC: 5939955. View

11.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

12.

Elze M, Gregson J, Baber U, Williamson E, Sartori S, Mehran R . Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017; 69(3):345-357. DOI: 10.1016/j.jacc.2016.10.060. View

13.

Kosiborod M, Esterline R, Furtado R, Oscarsson J, Gasparyan S, Koch G . Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021; 9(9):586-594. PMC: 8294807. DOI: 10.1016/S2213-8587(21)00180-7. View

14.

Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Florencio L, Cuadrado M, Plaza-Manzano G . Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med. 2021; 92:55-70. PMC: 8206636. DOI: 10.1016/j.ejim.2021.06.009. View

15.

Lee H, Chan Y, Chuang C, Li P, Yeh Y, Hsiao F . Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors. Eur Heart J Cardiovasc Pharmacother. 2023; 9(4):301-310. DOI: 10.1093/ehjcvp/pvad004. View

16.

Gupta R, Hussain A, Misra A . Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr. 2020; 74(6):864-870. PMC: 7220586. DOI: 10.1038/s41430-020-0652-1. View

17.

Braunwald E . SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2021; 43(11):1029-1030. DOI: 10.1093/eurheartj/ehab765. View

18.

Unsworth R, Wallace S, Oliver N, Yeung S, Kshirsagar A, Naidu H . New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care. 2020; 43(11):e170-e171. DOI: 10.2337/dc20-1551. View

19.

Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N . Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study. Diabetes Obes Metab. 2020; 23(1):263-269. PMC: 7537530. DOI: 10.1111/dom.14203. View

20.

The Lancet . Long COVID: 3 years in. Lancet. 2023; 401(10379):795. PMC: 9998094. DOI: 10.1016/S0140-6736(23)00493-2. View